Table 1 Characteristics of the whole cohort.
Memory clinic cohort | CU | p values | ||||
---|---|---|---|---|---|---|
All Patients | AD-MCI patients | AD dementia | All patients vs. CU | AD-MCI vs. AD Dementia | ||
Patient characteristics | N = 294 | N = 54 | N = 240 | N = 113 | ||
Age | 70.4 (6.4) | 71.3 (5.3) | 70.2 (6.7) | 72.3 (6.0) | 0.007a | 0.20a |
Women | 171 (58.2) | 33 (61.1) | 138 (57.5) | 54 (47.8) | 0.06b | 0.63b |
Education | 11.9 (3.6) | 12.7 (3.9) | 11.7 (3.5) | 14.1 (3.5) | <0.001a | 0.06a |
APOE ε4-positive* | 190 (73.9) | 34 (70.8) | 156 (74.6) | 42 (38.9) | <0.001b | 0.59b |
Cognition | ||||||
MMSE | 23.1 (4.4) | 26.3 (3.1) | 22.4 (4.3) | 29.2 (0.9) | <0.001a | <0.001 |
CDT accepted | 146 (52.0) | 41 (80.4) | 105 (45.7) | 108 (95.6) | <0.001b | <0.001b |
TMT A ≥ −2 SD | 171 (64.0) | 43 (87.8) | 128 (58.7) | 106 (93.8) | <0.001b | <0.001b |
TMT B ≥ −2 SD | 109 (43.3) | 35 (72.9) | 74 (36.3) | 105 (92.9) | <0.001b | <0.001b |
BPSD | ||||||
NPI-Q† | 3.4 (3.8) | 2.0 (2.9) | 3.7 (3.9) | 0.004a | ||
CSDD†† | 4.6 (4.1) | 2.8 (3.6) | 5.0 (4.1) | 0.001a | ||
CSF biomarkers | ||||||
Noradrenaline pmol/l | 17,871.1 (8109.3) | 18,986.2 (8985.8) | 17,620.2 (7897.4) | 14,998.9 (8062.7) | 0.001a | 0.37a |
Adrenaline pmol/l | 12,944.3 (6120.5) | 13,720.1 (6123.0) | 12,769.8 (6119.1) | 6225.6 (3382.5) | <0.001a | 0.16a |
Dopamine pmol/l | 2159.4 (898.7) | 2374.7 (863.1) | 2110.9 (901.2) | 2515.7 (934.0) | <0.001a | 0.18a |
Neurogranin pg/ml††† | 247.2 (86.9) | 231.0 (78.2) | 250.7 (88.3) | 209.5 (70.7) | <0.001a | 0.22a |
Amyloid β42 pg/ml | 561.2 (167.0) | 604.3 (174.5) | 551.5 (164.1) | 705.2 (206.8) | ** | 0.04a |
Total tau pg/ml | 704.9 (368.0) | 561.2 (271.2) | 737.3 (379.5) | 368.7 (149.2) | ** | 0.001a |
Phoshorylated tau181 pg/ml | 88.5 (37.3) | 76.5 (30.5) | 91.2 (38.1) | 59.5 (20.1) | ** | 0.008a |